Nebulized ensifentrine, an investigational inhaled anti-inflammatory, reduced exacerbations of chronic obstructive pulmonary disease (COPD) by 42 percent over 24 weeks — a significant benefit that could propel Verona Pharma to submit regulatory documents for a first-in-class treatment.